炎性腹主动脉瘤的腔内修复:单中心经验
本文回顾性分析单中心5例炎性腹主动脉瘤(IAAA)行腔内修复(EVAR)的经验,其中3例合并肾积水。结论认为EVAR技术可行、能有效隔绝动脉瘤并减少PAF,但对肾积水无改善作用,需密切随访。
要点
- EVAR可有效隔绝动脉瘤并促进瘤周纤维化消退或减少。
- 合并肾积水的患者EVAR后肾积水均持续存在,需密切随访。
核心结论
- EVAR治疗IAAA技术可行,能有效隔绝动脉瘤并减少瘤周纤维化,并发症率和死亡率可接受。
- EVAR对肾积水似乎无任何获益,对存在肾或输尿管受累的患者需更密切随访。
研究设计与样本
- 回顾性综述单中心腔内数据库,识别5例因IAAA接受EVAR的患者。
- 3例患者存在单侧输尿管受累并继发肾积水,1例患者出现腹膜后纤维化伴十二指肠狭窄。
主要发现
- 随访时间3至61个月,无失访。
- 所有患者获得主要技术成功。
- 1例患者术后3个月死亡,死于十二指肠狭窄持续存在(尽管后续内镜治疗和皮质激素治疗)。
- 动脉瘤囊在4例患者中逐渐缩小,1例保持不变。
- 瘤周纤维化在2例消退、2例减少、1例不变;术前诊断肾积水的3例患者肾积水均持续存在。
临床怎么用
- 对于IAAA,EVAR可作为开放手术的替代选择,尤其适用于希望避免炎性纤维化腹膜后分离的患者。
- 对合并肾积水或输尿管受累的IAAA患者,EVAR后需密切随访肾积水变化。
局限性
- 样本量小(仅5例),随访时间有限(3-61个月),为单中心回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammatory abdominal aortic aneurysm (IAAA) remained a rare cause of aneurysmal aortic disease, with incidences between 5% and 10%. The current treatment for IAAA consists of open surgical repair and endovascular aneurysm repair (EVAR). Avoiding an inflamed, fibrotic retroperitoneum is the driving force behind the desire to repair IAAA endovascularly. The latest published works confirm the promising results after EVAR for IAAA, but there is still a paucity of data regarding hydroureter and hydronephrosis. In this article, we describe our experience with 5 patients diagnosed with IAAA and treated by EVAR, of whom 3 presented with associated hydronephrosis. METHODS: A retrospective review of our endovascular database identified five patients who underwent EVAR for IAAA. Unilateral ureteral involvement in the inflammatory process was seen in 3 patients, accompanied by secondary hydronephrosis. One patient presented retroperitoneal fibrosis with duodenal stenosis. Primary outcomes were primary technical success, aneurysm-related mortality, change in aneurysm size, perianeurysmal fibrosis (PAF), and hydronephrosis. Secondary outcomes were requirement for reintervention, progression/resolution of symptoms, and short-term clinical success. RESULTS: Follow-up duration ranged from 3 to 61 months. No patients were lost to follow-up. Primary technical success was obtained in all patients. One patient died three months after the operation due to persistence of the duodenal stenosis in spite of subsequent endoscopic treatments and corticotherapy. The aneurysm sac progressively reduced in 4 patients and remained unchanged in one patient. PAF regressed in 2 patients, reduced in two, and remained unchanged in one patient. Hydronephrosis persisted in all three patients preoperatively diagnosed with this condition. No patient required subsequent intervention. Four patients had complete resolution of their symptoms at a follow-up visit at 1 month. CONCLUSIONS: This series suggests that EVAR for IAAA is technically feasible, excludes the aneurysm effectively, and reduces PAF with an acceptable morbidity and mortality rate. EVAR does not seem to offer any benefits for hydronephrosis, and closer follow-up in patients presenting renal or ureter involvement treated by EVAR is necessary.
引用
- Cardaci MB, Destraix R, Van Houte B, et al. Endovascular Repair of Inflammatory Aortic Aneurysms: Experience in a Single Center. Ann Vasc Surg. 2019. PMID: 30735769. doi:10.1016/j.avsg.2018.10.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。